Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Liver metastases--primary or multimodal therapy?].

R Ott1, A Wein, W Hohenberger

  • 1Chirurgische Klinik mit Poliklinik, Universität Erlangen-Nürnberg. Rudolf.Ott@chir.imed.uni-erlangen.de

Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|September 14, 2001
PubMed
Summary

Surgical resection remains the gold standard for colorectal liver metastases, but multimodal therapies are under investigation due to high recurrence rates. Current evidence does not strongly support neoadjuvant or adjuvant chemotherapy for improving outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scalable Cold-Atom Quantum Simulator for Two-Dimensional QED.

Physical review letters·2021
Same author

Acute outcome of chronic total occlusion (CTO) recanalizsation in the elderly.

The Medical journal of Malaysia·2017
Same author

Gender-based acute outcome in percutaneous coronary intervention of chronic total coronary occlusion.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2017
Same author

Validity of the J-CTO Score and the CL-Score for predicting successful CTO recanalization.

International journal of cardiology·2017
Same author

Distant metastases in colorectal carcinoma: A proposal for a new M1 subclassification.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2016
Same author

[Dysphagia--what is important for primary diagnosis in private practice?].

MMW Fortschritte der Medizin·2014

Area of Science:

  • Oncology
  • Surgical Oncology
  • Gastroenterology

Context:

  • Limited long-term benefit from surgical resection alone for liver metastases.
  • Only 20-25% of colorectal and neuroendocrine liver metastases are surgically resectable.
  • Recurrence rates after R0 resection for liver metastases range from 60-75%.

Purpose:

  • To evaluate multimodal therapeutic concepts for liver metastasis.
  • To assess the efficacy of neoadjuvant and adjuvant therapies in conjunction with resection.
  • To determine the optimal treatment strategy for colorectal liver metastases.

Summary:

  • Systemic treatment for non-resectable colorectal liver metastases can induce remission (50-60%) and enable secondary resection (14-38%).
  • Neoadjuvant therapy for resectable liver metastases is under investigation (EORTC study).

Related Experiment Videos

  • Adjuvant therapy and regional chemotherapy show contradictory or unproven efficacy for liver metastases.

    • Impact:

    • Surgical resection with clear margins remains the gold standard for colorectal liver metastases.
    • Multimodal approaches, including neoadjuvant/adjuvant chemotherapy and thermal ablation, should be limited to clinical trials.
    • Further research is needed to optimize treatment strategies and improve patient outcomes for liver metastases.